Lee S, Jeong S, Kim Y, Noh J, Rho K, Kim H
J Immunother Cancer. 2025; 13(2).
PMID: 40010769
PMC: 11865743.
DOI: 10.1136/jitc-2024-010193.
Cheng X, Meng F, Wang R, Liu S, Li Q, Chen B
BMC Cancer. 2024; 24(1):1518.
PMID: 39696104
PMC: 11657211.
DOI: 10.1186/s12885-024-13298-z.
Raskov H, Orhan A, Agerbaek M, Gogenur I
Heliyon. 2024; 10(14):e34361.
PMID: 39114075
PMC: 11305202.
DOI: 10.1016/j.heliyon.2024.e34361.
Anguera G, Mulet M, Zamora C, Osuna-Gomez R, Barba A, Sullivan I
Biomedicines. 2024; 12(5).
PMID: 38790920
PMC: 11117542.
DOI: 10.3390/biomedicines12050958.
Le Chapelain O, Jadoui S, Gros A, Barbaria S, Benmeziane K, Ollivier V
J Exp Clin Cancer Res. 2024; 43(1):84.
PMID: 38493157
PMC: 10944607.
DOI: 10.1186/s13046-024-03001-2.
Editorial: Platelets in tumor biology: from molecular mechanisms to clinical applications.
Aris M, Sood A, Zaslavsky A
Front Cell Dev Biol. 2024; 12:1373463.
PMID: 38415273
PMC: 10898350.
DOI: 10.3389/fcell.2024.1373463.
The dynamic role of platelets in cancer progression and their therapeutic implications.
Li S, Lu Z, Wu S, Chu T, Li B, Qi F
Nat Rev Cancer. 2023; 24(1):72-87.
PMID: 38040850
DOI: 10.1038/s41568-023-00639-6.
Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients.
Araki T, Kanda S, Ide T, Sonehara K, Komatsu M, Tateishi K
ESMO Open. 2023; 8(6):102030.
PMID: 37852033
PMC: 10774871.
DOI: 10.1016/j.esmoop.2023.102030.
Platelet Contributions to the (Pre)metastatic Tumor Microenvironment.
Roweth H
Semin Thromb Hemost. 2023; 50(3):455-461.
PMID: 37832586
PMC: 11177183.
DOI: 10.1055/s-0043-1776005.
A role for platelets in metabolic reprogramming of tumor-associated macrophages.
Kang Y, Amoafo E, Entsie P, Beatty G, Liverani E
Front Physiol. 2023; 14:1250982.
PMID: 37693009
PMC: 10484008.
DOI: 10.3389/fphys.2023.1250982.
Platelets as a prognostic factor for patients with adenocarcinoma of the gastroesophageal junction.
Feka J, Jomrich G, Winkler D, Ilhan-Mutlu A, Kristo I, Paireder M
Langenbecks Arch Surg. 2023; 408(1):351.
PMID: 37673810
PMC: 10482770.
DOI: 10.1007/s00423-023-03093-y.
Reprogramming the immunosuppressive tumor microenvironment: exploiting angiogenesis and thrombosis to enhance immunotherapy.
Shafqat A, Omer M, Ahmed E, Mushtaq A, Ijaz E, Ahmed Z
Front Immunol. 2023; 14:1200941.
PMID: 37520562
PMC: 10374407.
DOI: 10.3389/fimmu.2023.1200941.
Effects of the interactions between platelets with other cells in tumor growth and progression.
Li Y, Wang H, Zhao Z, Yang Y, Meng Z, Qin L
Front Immunol. 2023; 14:1165989.
PMID: 37153586
PMC: 10158495.
DOI: 10.3389/fimmu.2023.1165989.
Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring.
Liu C, Fang F, Kong Y, ElGabry E
Diagn Pathol. 2023; 18(1):48.
PMID: 37076889
PMC: 10114344.
DOI: 10.1186/s13000-023-01318-8.
Interactions between Platelets and Tumor Microenvironment Components in Ovarian Cancer and Their Implications for Treatment and Clinical Outcomes.
Oncul S, Cho M
Cancers (Basel). 2023; 15(4).
PMID: 36831623
PMC: 9953912.
DOI: 10.3390/cancers15041282.
Blood-Based Biomarker Analysis for Predicting Efficacy of Chemoradiotherapy and Durvalumab in Patients with Unresectable Stage III Non-Small Cell Lung Cancer.
Park C, Lee S, Cho H, Oh H, Kim Y, Kim Y
Cancers (Basel). 2023; 15(4).
PMID: 36831494
PMC: 9953836.
DOI: 10.3390/cancers15041151.
The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis.
Shi Q, Ji T, Tang X, Guo W
Cell Oncol (Dordr). 2023; 46(3):521-532.
PMID: 36652166
DOI: 10.1007/s13402-023-00773-1.
Screening and validation of platelet activation-related lncRNAs as potential biomarkers for prognosis and immunotherapy in gastric cancer patients.
Yuan M, Jia Y, Xing Y, Wang Y, Liu Y, Liu X
Front Genet. 2022; 13:965033.
PMID: 36186426
PMC: 9515443.
DOI: 10.3389/fgene.2022.965033.
PD-L1 Regulates Platelet Activation and Thrombosis Caspase-3/GSDME Pathway.
Li Y, Xin G, Li S, Dong Y, Zhu Y, Yu X
Front Pharmacol. 2022; 13:921414.
PMID: 35784685
PMC: 9240427.
DOI: 10.3389/fphar.2022.921414.
Liquid Biopsy Assessment of Circulating Tumor Cell PD-L1 and IRF-1 Expression in Patients with Advanced Solid Tumors Receiving Immune Checkpoint Inhibitor.
Kennedy L, Lu J, Kuehn S, Ramirez A, Lo E, Sun Y
Target Oncol. 2022; 17(3):329-341.
PMID: 35696014
PMC: 9674018.
DOI: 10.1007/s11523-022-00891-0.